国际肿瘤学杂志

国际肿瘤学杂志 ›› 2014, Vol. 41 ›› Issue (4): 297-301.doi: 10.3760/cma.j.issn.1673422X.2014.04.018

• 论著 • 上一篇    下一篇

123I-血管内皮生长因子结合位点在人类肿瘤细胞的表现特征

陈文标, 李树人, 齐素文, 陈德珩, 戴勇   

  1. 518000 深圳，暨南大学第二临床学院；深圳市人民医院临床医学研究中心（陈文标、陈德珩、戴勇）；奥地利维也纳大学核医学部(李树人)；深圳大学医学院生物医学工程学院（齐素文）
  • 出版日期:2014-04-08 发布日期:2014-03-17
  • 通讯作者: 戴勇，Email: daiyong2222@gmail.com E-mail:daiyong2222@gmail.com
  • 基金资助:

    深圳市科技研发资金国际科技合作项目(ZYA201106030005A)

Expression characteristics of 123Ivascular endothelial growth factorbinding sites on tumor cells

CHEN  Wen-Biao, LI  Shu-Ren, QI  Su-Wen, CHEN  De-Hang, DAI  Yong   

  1. Second Clinical Medical College of Ji′nan University; Clinical Medical Research Center, Shenzhen People′s Hospital, Shenzhen 518000, China
  • Online:2014-04-08 Published:2014-03-17
  • Contact: Dai Yong E-mail:daiyong2222@gmail.com
  • Supported by:

     

     

PDF

1561

摘要： 目的探索肿瘤血管内皮生长因子（VEGF）受体（VEGFR）在人类肿瘤细胞的表现特征。方法将123IVEGF165和123IVEGF121标记于人脐静脉内皮细胞（HUVEC）、人类肿瘤细胞株（HMC1、A431、KU812、U937、HEP1、HEPG2、HEP3B、Raji）、多种人体肿瘤及邻近的非瘤组织和外周血液细胞。统计特异性结合位点最大结合容量（Bmax）值、解离常数（Kd）以及放射性同位素的50%特异性结合所需浓度（IC50）数值。判断各种细胞与123IVEGF165和123IVEGF121 结合亲和力、数量、特异性。结果在HUVEC表面发现两种123IVEGF165结合位点，而123IVEGF121是单类结合位点。123IVEGF121位于特定细胞株（HUVEC、HEP1、HMC1）和特殊的早期肿瘤（早期黑色素瘤、乳腺导管内癌、卵巢癌和脑膜瘤）中。与外周血液细胞和非瘤组织相比，肿瘤细胞的VEGFR数量明显较多。在123IVEGF165标记的VEGFR中，早期黑色素瘤、乳腺导管内癌、肝细胞癌、乳头状甲状腺癌、卵巢癌、肾细胞癌的Bmax值分别为45±13、13±3、25±8、5±2、42±12、20±6。而在123IVEGF121标志的VEGFR中，早期黑色素瘤、乳腺导管内癌、卵巢癌的Bmax值分别为30±8、8±3、20±6。123IVEGF165和123IVEGF121与诸多人体肿瘤细胞或组织具有特异性结合能力。与123IVEGF121相比，123IVEGF165可与更多不同种类的肿瘤细胞相结合，且容量大。结论123IVEGF165可能是肿瘤体内成像的一个潜在有效靶点，有望用于肿瘤的诊断与治疗。

关键词: 血管内皮生长因子类, 肿瘤, 放射性核素成像

Abstract: ObjectiveTo explore the expression characteristics of vascular endothelial growth factor (VEGF) receptor (VEGFR). MethodsThe 123IVEGF165 and 123IVEGF121 were marked to human umbilical vein endothelial cell (HUVEC), several human tumor cell lines (HMC1, A431, KU812, U937, HEP1, HEPG2, HEP3B and Raji), a variety of human tumors and adjacent nonneoplastic tissues as well as peripheral blood cells. Then， the specific binding site maximal binding capacity (Bmax), dissociation constant (Kd) and concentration of 50% required specific binding (IC50) were analyzed. The affinity, quantity and specificity of different cells combined with 123IVEGF165 and 123IVEGF121 were judged. ResultsTwo kinds of analogous 123IVEGF165 binding sites on the surface of HUVEC were found. While, there was only one kind of 123IVEGF121 binding site.123IVEGF121 was found on the special cell lines (HUVEC, HEP1 and HMC1) and special early tumors (early melanoma, ductal breast cancer, ovarian cancer and meningioma). Compared with peripheral blood cells and adjacent nonneoplastic tissues,  the number of VEGFR of tumor cells was bigger. Among the 123IVEGF165 marked VEGFR, the Bmax value of early melanoma, ductal breast cancer, hepatocellular carcinoma, papillary thyroid carcinoma, ovarian carcinoma, renal cell carcinoma were 45±13, 13±3, 25±8, 5±2, 42±12, 20±6, respectively. While among the 123IVEGF121 marked VEGFR, the Bmax value of early melanoma, ductal breast cancer, ovarian carcinoma were 30±8, 8±3, 20±6. 123IVEGF165 and 123IVEGF121 had specific binding capacity with a variety of human tumor cells and tissues. Compared with 123IVEGF121, there were more different kinds of tumor cells could be bound to 123IVEGF165 with higher capacity. Conclusion123IVEGF165 may be a potential target of tumor imaging in vivo, and it is expected to be used to diagnose and treat tumors.

Key words: Vascular endothelial growth factors, Neoplasms, Radionuclide imaging